<DOC>
	<DOCNO>NCT00040131</DOCNO>
	<brief_summary>The purpose study determine single dose IL-10 compare placebo safe effective reduce incidence post-ERCP acute pancreatitis subject increase risk .</brief_summary>
	<brief_title>Safety Efficacy Study IL-10 ( Tenovil TM ) Prevention Post-ERCP Acute Pancreatitis ( Study P02580 ) ( TERMINATED )</brief_title>
	<detailed_description />
	<mesh_term>Pancreatitis</mesh_term>
	<mesh_term>Pancreatic Diseases</mesh_term>
	<mesh_term>Gallbladder Diseases</mesh_term>
	<mesh_term>Biliary Tract Diseases</mesh_term>
	<mesh_term>Bile Duct Diseases</mesh_term>
	<criteria>Inclusion criterion : Adults weigh 125 kg undergo ERCP follow : Evaluate recurrent abdominal pain ; Evaluate unexplained recurrent pancreatitis ; Evaluate prior postERCP pancreatitis ; Treatment pancreatic disorder ; Treatment Common Bile Duct Stones ( without jaundice ) Exclusion criterion : Active ( acute ) pancreatitis ; Chronic pancreatitis ( moderate severe case ) ; ERCP perform second procedure biliary tract ; Patients previously pancreatic sphincterotomy ; Known suspect pancreatic cancer cancer Papilla Vater ; Known suspect malignancy ; History , current clot bleeding problem ; Moderate severe Anemia ; Low platelet count</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>